Structure-activity analysis of synthetic α-thrombin-receptor-activating peptides

• Published in: Biochemical journal 1993-06, Vol.292 (3), p.667-671
• Main Authors: VAN OBBERGHEN-SCHILLING, E, RASMUSSEN, U. B, VOURET-CRAVIARI, V, LENTES, K.-U, PAVIRANI, A, POUYSSEGUR, J
• Format: Article
• Language: English
• Subjects: 1-Methyl-3-isobutylxanthine - pharmacology; Adenylyl Cyclase Inhibitors; Amino Acid Sequence; Animals; Biological and medical sciences; Cell Line; Cell receptors; Cell structures and functions; Colforsin - pharmacology; Cricetinae; Cricetulus; DNA Replication - drug effects; Enzyme Activation; Fibroblast Growth Factor 2 - pharmacology; Fundamental and applied biological sciences. Psychology; Humans; Inositol Phosphates - metabolism; Kinetics; Lung; Miscellaneous; Molecular and cellular biology; Molecular Sequence Data; Oligopeptides - chemical synthesis; Oligopeptides - pharmacology; Receptors, Cell Surface - drug effects; Receptors, Cell Surface - metabolism; Receptors, Thrombin; Recombinant Proteins - pharmacology; Structure-Activity Relationship; Thrombin - metabolism; Thrombin - pharmacology; Type C Phospholipases - metabolism
• ISSN: 0264-6021; 1470-8728
• DOI: 10.1042/bj2920667

alpha-Thrombin stimulates G-protein-coupled effectors leading to secretion and aggregation in human platelets, and to a mitogenic response in CCL39 hamster fibroblasts. alpha-Thrombin receptors can be activated by synthetic peptides corresponding to the receptor sequence starting with serine-42, at the proposed cleavage site. We have previously determined that the agonist domain of receptor-activating peptides resides within the five N-terminal residues [Vouret-Craviari, Van Obberghen-Schilling, Rasmussen, Pavirani, Lecocq and Pouysségur (1992) Mol. Biol. Cell. 3, 95-102], although the 7-residue peptide (SFFLRNP) corresponding to the hamster alpha-thrombin receptor was 10 times more potent than the 5-residue peptide for activation of human platelets. In the present study we have analysed the role of individual amino acids in receptor activation by using a series of modified hexa- or hepta-peptides derived from the human alpha-thrombin-receptor sequence. Cellular events examined here include phospholipase C activation, adenylyl cyclase inhibition and DNA synthesis stimulation in non-transformed CCL39 fibroblasts and a tumorigenic variant of that line (A71 cells). Modification of the peptide sequence had similar functional consequence for each of the assays described, indicating that either a unique receptor or pharmacologically indistinguishable receptor subtypes activate distinct G-protein signalling pathways. Furthermore, we found that: (1) the N-terminal serine can be replaced by small or intermediately sized amino acids (+/- hydroxyl groups) without loss of activity. However, its replacement by an aromatic side-chain or omission of the N-terminal amino group severely reduces activity. (2) An aromatic side-chain on the penultimate N-terminal residue appears to play a critical role since phenylalanine in this position can be substituted by tyrosine without complete loss of activity whereas an alanine in its place is not tolerated. (3) Deletion of the first, second or third N-terminal residue leads to a loss of activity, suggesting that a defined spacing of more than one structural component may be important for ligand-receptor interaction. Finally, we did not observe an antagonistic effect of the inactive peptides on phospholipase C activation or DNA synthesis induced by alpha-thrombin (1 nM) or SFLLRNP (3 microM).